Margaret A. Park

2.7k citations

55 papers · 2.1k indexed · h-index 28

Molecular Biology top 5%
Oncology top 5%
Epidemiology top 5%
Cell Biology top 5%
Genetics top 10%

Co-authors: Paul Dent Steven Grant Adly Yacoub Paul B. Fisher Clint Mitchell Mohamed Rahmani Hossein A. Hamed David T. Curiel
Topics: Autophagy in Disease and Therapy (11 papers)Endoplasmic Reticulum Stress and Disease (10 papers)Cell death mechanisms and regulation (9 papers)
Cited by: Physiology Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Cancer Research
Partner nations: United States Russia Canada

In The Last Decade

Margaret A. Park

53 papers receiving 2.1k citations

Peers

Countries citing papers authored by Margaret A. Park

Since Specialization

Citations

This map shows the geographic impact of Margaret A. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret A. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret A. Park more than expected).

Fields of papers citing papers by Margaret A. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret A. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret A. Park. The network helps show where Margaret A. Park may publish in the future.

Co-authorship network of co-authors of Margaret A. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret A. Park. A scholar is included among the top collaborators of Margaret A. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret A. Park. Margaret A. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells 2023 ·Frontiers in Oncology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Margaret A. Park,Anders Berglund,Stanley M. Stevens,Meera Nanjundan	2
2	CCAR-1 works together with the U2AF large subunit UAF-1 to regulate alternative splicing 2023 ·RNA Biology ·(unknown),(unknown),Dale Chaput,Margaret A. Park,Sandy D. Westerheide	0
3	Caspase-9b Interacts Directly with cIAP1 to Drive Agonist-Independent Activation of NF-κB and Lung Tumorigenesis 2016 ·Cancer Research ·Ngoc Vu,Margaret A. Park,Michael D. Shultz,Gamze B. Bulut,Amy C. Ladd,Charles E. Chalfant	14
4	Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis 2016 ·Journal of Biological Chemistry ·(unknown),Ngoc Vu,Michael D. Shultz,Jacqueline C. Shultz,(unknown),(unknown),Adly Yacoub,Paul Dent,Paul B. Fisher,Margaret A. Park,Charles E. Chalfant	12
5	The Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer 2015 ·Journal of Biological Chemistry ·(unknown),Ngoc Vu,Brian P. Griffin,(unknown),Kellie J. Archer,Charles E. Chalfant,Margaret A. Park	29
6	SRSF1 Regulates the Alternative Splicing of Caspase 9 Via A Novel Intronic Splicing Enhancer Affecting the Chemotherapeutic Sensitivity of Non–Small Cell Lung Cancer Cells 2011 ·Molecular Cancer Research ·Jacqueline C. Shultz,Rachel W. Goehe,(unknown),Dayanjan S. Wijesinghe,(unknown),Autumn Massiello,Amy J. Hawkins,(unknown),(unknown),Margaret A. Park,Charles E. Chalfant	73
7	Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells 2011 ·Cancer Research ·(unknown),Margaret A. Park,Adly Yacoub,Hossein A. Hamed,Yong Tang,Nichola Cruickshanks,Patrick Eulitt,(unknown),Gary Tye,Matthew E. Burow,Paul B. Fisher,Richard G. Moran,Kenneth P. Nephew,Steven Grant,Paul Dent	97
8	Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway 2010 ·Cancer Research ·Margaret A. Park,Clint Mitchell,Guo Zhang,Adly Yacoub,Jeremy C. Allegood,Dieter Häussinger,Roland Reinehr,Andrew C. Larner,Sarah Spiegel,Paul B. Fisher,Christina Voelkel‐Johnson,Besim Öğretmen,Steven Grant,Paul Dent	86
9	Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells 2010 ·Molecular Cancer Therapeutics ·Margaret A. Park,Roland Reinehr,Dieter Häussinger,Christina Voelkel‐Johnson,Besim Öğretmen,Adly Yacoub,Steven Grant,Paul Dent	74
10	17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species 2010 ·Molecular Cancer Therapeutics ·Teneille Walker,Clint Mitchell,Margaret A. Park,Adly Yacoub,Mohamed Rahmani,Dieter Häussinger,Roland Reinehr,Christina Voelkel‐Johnson,Paul B. Fisher,Steven Grant,Paul Dent	16
11	The development of MDA-7/IL-24 as a cancer therapeutic 2010 ·Pharmacology & Therapeutics ·Paul Dent,(unknown),(unknown),Margaret A. Park,Rupesh Dash,Sujit K. Bhutia,Devanand Sarkar,Xiang‐Yang Wang,Pankaj Gupta,Luni Emdad,Irina V. Lebedeva,Moira Sauane,Zhao-zhong Su,Mohamed Rahmani,William C. Broaddus,Harold F. Young,Maciej S. Lesniak,Steven Grant,David T. Curiel,Paul B. Fisher	50
12	Enhancingmda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery 2010 ·Cancer Biology & Therapy ·Patrick Eulitt,Margaret A. Park,(unknown),(unknown),Yang Chen,Igor P. Dmitriev,Adly Yacoub,David T. Curiel,Paul B. Fisher,Paul Dent	25
13	mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity 2010 ·Cytokine & Growth Factor Reviews ·Rupesh Dash,Sujit K. Bhutia,Belal Azab,Zhao-zhong Su,Bridget A. Quinn,(unknown),Swadesh K. Das,(unknown),Seok‐Geun Lee,Margaret A. Park,Adly Yacoub,Mohamed Rahmani,Luni Emdad,Igor P. Dmitriev,Xiang‐Yang Wang,Devanand Sarkar,Steven Grant,Paul Dent,David T. Curiel,Paul B. Fisher	91
14	MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism 2009 ·Molecular Cancer Therapeutics ·Margaret A. Park,Teneille Walker,Aditi Pandya Martin,Jeremy C. Allegood,Nicollaq Vozhilla,Luni Emdad,Devanand Sarkar,Mohamed Rahmani,Martin Graf,Adly Yacoub,Constantinos Koumenis,Sarah Spiegel,David T. Curiel,Christina Voelkel‐Johnson,Steven Grant,Paul B. Fisher,Paul Dent	40
15	Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms 2009 ·Molecular Pharmacology ·Teneille Walker,Clint Mitchell,Margaret A. Park,Adly Yacoub,Martin Graf,Mohamed Rahmani,Peter J. Houghton,Christina Voelkel‐Johnson,Steven Grant,Paul Dent	81
16	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation 2008 ·Clinical Cancer Research ·Guo Zhang,Margaret A. Park,Clint Mitchell,Hossein A. Hamed,Mohamed Rahmani,Aditi Pandya Martin,David T. Curiel,Adly Yacoub,Martin R. Graf,Ray Lee,John D. Roberts,Paul B. Fisher,Steven Grant,Paul Dent	101
17	Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 2008 ·Molecular Cancer Therapeutics ·Margaret A. Park,Guo Zhang,Clint Mitchell,Mohamed Rahmani,Hossein A. Hamed,Michael P. Hagan,Adly Yacoub,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	41
18	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation 2008 ·Cancer Biology & Therapy ·Margaret A. Park,Guo Zhang,Aditi Pandya Martin,Hossein A. Hamed,Clint Mitchell,Philip B. Hylemon,Martin R. Graf,Mohamed Rahmani,Kevin M. Ryan,Xiang Liu,Sarah Spiegel,James N. Norris,Paul B. Fisher,Steven Grant,Paul Dent	146
19	MEK1/2 inhibition promotes Taxotere® lethality in mammary tumors in vivo 2006 ·Cancer Biology & Therapy ·Adly Yacoub,Donna Gilfor,William Hawkins,Margaret A. Park,David E. Hanna,Michael P. Hagan,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	9
20	OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells 2006 ·Molecular Pharmacology ·Adly Yacoub,Margaret A. Park,David E. Hanna,Young Ki Hong,Clint Mitchell,(unknown),Hisashi Harada,Garth Powis,Ching-Shih Chen,Constantinos Koumenis,Steven Grant,Paul Dent	66

About Margaret A. Park

Margaret A. Park is a scholar working on Cell Biology, Physiology and Oncology, having authored 55 papers that have together received 2.1k indexed citations. Recurring topics across this work include Autophagy in Disease and Therapy (11 papers), Endoplasmic Reticulum Stress and Disease (10 papers) and Cell death mechanisms and regulation (9 papers). The work is most often cited by research in Physiology (117 citations), Oncology (574 citations) and Molecular Biology (1.4k citations). Margaret A. Park has collaborated with scholars based in United States, Russia and Canada. Frequent co-authors include Paul Dent, Steven Grant, Adly Yacoub, Paul B. Fisher, Clint Mitchell, Mohamed Rahmani, Hossein A. Hamed, David T. Curiel, Charles E. Chalfant and Guo Zhang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact